All Releases
 |
Myrexis, Inc. Announces the Cancellation of Its Upcoming Shareholder Meeting
Jan 23, 2013
|
12.5 KB |
|
| |
Board Approves a Special Cash Distribution and the Appointment of a New Director and Chief Executive Officer Tax Benefits Preservation Rights Plan Remains in Effect
SALT LAKE CITY, Jan. 23, 2013 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX) today announced that its Board of Directors has unanimously determined to cancel the special meeting of...
|
|
Myrexis, Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
Nov 9, 2012
|
15.4 KB |
|
| |
SALT LAKE CITY, Nov. 9, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets. In connection w...
|
|
Myrexis Reports Fiscal Year 2012 Results and Provides Company Update
Sep 13, 2012
|
17.1 KB |
|
| |
SALT LAKE CITY, Sept. 13, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), today provided an update on recent developments and reported results for its fiscal full year ended June 30, 2012.Company Update
In February 2012, the Company announced that it had suspended development activity on all of its preclinical and clinical programs and re...
|
|
Myrexis Announces Death of Chief Executive Officer Richard B. Brewer, Trailblazing Biotechnology Industry Veteran and Patient Advocate
Aug 15, 2012
|
8.0 KB |
|
| |
...
|
|
Myrexis Appoints New Executive Management Team in Alignment With Strategic Initiatives
May 11, 2012
|
11.1 KB |
|
| |
SALT LAKE CITY, May 11, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX) announced today that its Board of Directors has appointed Richard B. Brewer as President and Chief Executive Officer, and David W. Gryska as Chief Operating Officer, effective today, May 11, 2012. In addition, both Mr. Brewer and Mr. Gryska have been appointed to Myrexis' ...
|
|
Myrexis Reports Third Quarter Fiscal Year 2012 Results
May 10, 2012
|
15.7 KB |
|
| |
SALT LAKE CITY, May 10, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX) today reported financial results for its third fiscal quarter ended March 31, 2012.
As announced previously in February 2012, Myrexis, Inc. made the decision to suspend development activities on all its preclinical and clinical programs. The Company also announced that...
|
|
Myrexis Adopts Tax Benefits Preservation Rights Plan to Protect Use of Net Operating Losses Replacing Existing Shareholder Rights Plan
Mar 30, 2012
|
9.9 KB |
|
| |
SALT LAKE CITY, March 30, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX) announced today that its Board of Directors has adopted a Tax Benefits Preservation Rights Plan in the form of a Rights Agreement designed to help protect and preserve its substantial tax attributes primarily associated with net operating loss carryforwards (NOLs) and re...
|
|
Myrexis Initiates Resource Alignment
Mar 1, 2012
|
8.6 KB |
|
| |
SALT LAKE CITY, March 1, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX) today announced that it has initiated an alignment of its resources including a reduction in force consistent with its February 15, 2012 announcement. The Company will have 30 employees remaining by March 31, 2012, the end of its third fiscal quarter and expects to have a...
|
|
Myrexis Retains Investment Bank to Explore
Feb 15, 2012
|
8.5 KB |
|
| |
Salt Lake City, (February 15, 2012) - Myrexis, Inc. (Nasdaq: MYRX), a biotechnology company focused on the development of small molecule therapeutics, today announced that its Board of Directors has retained Stifel Nicolaus Weisel, an investment banking firm, to assist it in reviewing and evaluating a full range of strategic alternatives ...
|
|
Myrexis Reports Second Quarter Fiscal Year 2012 Results
Feb 9, 2012
|
17.3 KB |
|
| |
SALT LAKE CITY, Feb. 9, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today reported financial results for its second fiscal quarter ended December 31, 2011.
Robert J. Lollini, President and...
|
|
Myrexis to Hold Conference Call to Discuss Second Fiscal Quarter 2012 Financial Results
Feb 3, 2012
|
8.9 KB |
|
| |
SALT LAKE CITY, Feb. 3, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action, today announced it will hold a conference call on Thursday, February 9, 2012 at 4:30 p.m. ET (1:30 p.m. PT) to discuss financia...
|
|
Myrexis Announces Corporate Reorganization to Focus on Development Objectives
Nov 18, 2011
|
11.2 KB |
|
| |
Internal Resources Realigned to Support Development StrategyFurther 20% Reduction in Workforce and $1.8 Million in Annual Cost Reduction
SALT LAKE CITY, Nov. 18, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mech...
|
|
Myrexis Presents at 2011 EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Symposium
Nov 14, 2011
|
14.4 KB |
|
| |
SALT LAKE CITY, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced that it presented two posters at the 2011 European Organization for Research and Treatment of Cancer (EORTC...
|
|
Myrexis Reports First Quarter Fiscal Year 2012 Results
Nov 9, 2011
|
17.3 KB |
|
| |
SALT LAKE CITY, Nov. 9, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today reported financial results for its fiscal first quarter ended September 30, 2011.
Robert J. Lollini, President and...
|
|
CORRECTION -- Myrexis to Hold Conference Call to Discuss First Quarter 2012 Financial Results
Nov 3, 2011
|
6.3 KB |
|
| |
SALT LAKE CITY, Nov. 3, 2011 (GLOBE NEWSWIRE) -- In a press release issued earlier today by Myrexis, Inc. (Nasdaq:MYRX) with the same headline, please note that the conference call will be held on Wednesday, November 9, 2011. All other information remains accurate.CONTACT: Myrexis, Inc.
Wayne Laslie
Chief Operating Officer
...
|
|
Myrexis to Present at 2011 EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Symposium
Nov 3, 2011
|
10.0 KB |
|
| |
SALT LAKE CITY, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced it will present two posters at the 2011 European Organization for Research and Treatment of Cancer (EORTC), ...
|
|
Myrexis to Hold Conference Call to Discuss First Quarter 2012 Financial Results
Nov 3, 2011
|
9.6 KB |
|
| |
SALT LAKE CITY, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced it will hold a conference call on Thursday, November 9, 2011 at 4:30 p.m. ET (1:30 p.m. PT) to discuss finan...
|
|
Myrexis Appoints Jason M. Aryeh to its Board of Directors
Oct 20, 2011
|
9.8 KB |
|
| |
SALT LAKE CITY, Oct. 20, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced the appointment of Jason M. Aryeh, Founder and General Partner of JALAA Equities L.P., to its Board of Dire...
|
|
Myrexis to Participate in the 2011 UBS Global Life Sciences Conference
Sep 14, 2011
|
9.5 KB |
|
| |
SALT LAKE CITY, Sept. 14, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action, today announced that Robert Lollini, President and Chief Executive Officer, will be presenting at the 2011 UBS Global Life Sc...
|
|
Myrexis to Present at 2011 Rodman and Renshaw Healthcare Conference
Sep 9, 2011
|
9.9 KB |
|
| |
SALT LAKE CITY, Sept. 9, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action, today announced that Robert Lollini, President and Chief Executive Officer, will be presenting at the 2011 Rodman and Renshaw ...
|
|
|
